Vernal Keratoconjunctivitis Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Vernal Keratoconjunctivitis Drugs Market is segmented By Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Others), By Treatment Type (Mast Cell Stabilizers, Antihistamines, Corticosteroids, Immunosuppressive Medications, Other Medications), By Dosage Form (Ointment, Gel, Tablets, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Market Overview

The Global Vernal Keratoconjunctivitis Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

Vernal keratoconjunctivitis (VKC) is a recurrent ocular inflammatory disease that occurs seasonally. A rare condition most commonly found in men between the ages of 3 and 20 years, VKC accounts for roughly 0.1 to 0.5 percent of ocular disease. The disease also affects children and young adults and tends to occur more frequently in dry, warm climates. Some people experience symptoms year round; however, the peak season for VKC is between April and August.

Drugs for VKC are generally used to treat the condition's painful and bothersome symptoms. Itching, redness, burning, tearing, and a feeling of a foreign body in the eyes are some of these symptoms. The conjunctiva and, occasionally, the cornea are inflamed in VKC. Immunosuppressive medicines and corticosteroid eye drops can help lessen this inflammation, which can ease symptoms and prevent problems. 

Market Scope

For more details of the report - Request for sample

Market Dynamics: Drivers and Restraints

The rise of product approvals

The approval of new VKC drugs by regulatory agencies can open up new avenues for treatment. These approvals can result in increased market competition and the availability of more treatment options. For instance, on June 24, 2021, Emeryville, California – Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, the U.S. Food and Drug Administration (FDA) had approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. Thus rise of approvals helps to drive the market growth.

The market is significantly influenced by the prevalence and incidence of VKC. There is an ongoing demand for medications and treatments to address VKC because it is a chronic and recurrent disorder while being relatively uncommon. Being an allergic eye disease, VKC may become more common as the prevalence of allergic diseases like hay fever and asthma rises. This may increase the number of potential patients and increase demand for VKC drugs. New medications and therapies that are developed as a result of advances in research and development for VKC treatments may spur market expansion. Expanding therapy options and enhancing patient outcomes are both possible with new, more potent drugs.

Restraint

The Vernal Keratoconjunctivitis (VKC) market, like any healthcare market, faces various restraining factors that can impact its growth and development. For instance, given that VKC combines symptoms with other eye disorders, it can be difficult to get an accurate diagnosis. This may result in an incorrect or incomplete diagnosis, delaying necessary care and changing consumer demand. Some VKC treatments can be pricey, especially immunosuppressive meds and new therapies. In areas with limited healthcare resources, high treatment prices may discourage people from seeking care or restrict market expansion. When taken for an extended period of time, several VKC drugs, such as corticosteroids, may cause negative effects. A patient's lack of compliance and hesitation to take these treatments due to side effects may have a negative impact on the market's expansion.

Segment Analysis

The global vernal keratoconjunctivitis market is segmented based on drug type, treatment type, dosage form, distribution channel and region.

The Mast Cell Stabilizers Segment From the Treatment Type Segment Accounted For Approximately 41.7% of Vernal Keratoconjunctivitis Share

A class of drugs called mast cell stabilisers is frequently used to treat the signs and symptoms of Vernal Keratoconjunctivitis (VKC), an allergic eye disorder. These drugs assist in reducing VKC-related symptoms and reducing inflammation. When mast cells are exposed to allergens, mast cell stabilisers like Cromolyn sodium and Nedocromil sodium act by inhibiting the release of histamine and other inflammatory mediators. 

They prevent mast cells from degranulating and releasing their contents by stabilising their cell membranes. Mast cell stabilisers are suitable for addressing chronic illnesses like VKC and are safe for long-term use. Mast cell stabilisers can be taken for a longer period of time than corticosteroids, which are normally not advised due to potential side effects. Thus above factors accelerate the segment growth.

Geographical Analysis

Rising healthcare espendiature in the North American region

North America is expected to acquire a highest market share over the forecast period. This growth is attributable to the increasing awareness of ophthalmic allergies and as awareness of VKC and other allergic eye conditions increases among both healthcare providers and the general public and rise of health expenditure accelerates the region growth. 

For instance, the expense of healthcare in the US is among the highest in the world. Spending on healthcare in the United States in 2021 was $4.3 trillion, or nearly $12,900 per person. Other wealthy nations only charge roughly half as much for healthcare on average per person. Healthcare expense had been increasing for a long time prior to the COVID-19 epidemic, even if it was made worse by it. As a result, increasing healthcare costs contribute to regional growth.

COVID-19 Impact Analysis

Many healthcare systems were overburdened during the pandemic's peak, which led to the cancellation or postponement of non-urgent medical visits and treatments. The capacity of VKC patients to receive prompt medical attention and treatment could have been hampered by this disturbance. COVID-Lockdowns and limitations may have prevented 19 people from being exposed to outdoor allergens like pollen, which can cause VKC symptoms. 

Even if some people's symptoms may have been momentarily relieved by this lowering, it could not be a viable or preferable long-term option. The epidemic caused a greater emphasis on good hygiene habits, such as the necessity of washing hands and refraining from rubbing one's eyes. As eye rubbing can exacerbate symptoms and consequences, these procedures may be helpful for VKC patients.

Competitive Landscape

The major global players in the market include Novartis AG, Santen Pharmaceutical Co., Ltd., Akari Therapeutics, iCo Therapeutics Inc, Jabs Biotech Pvt. Ltd, Teva Pharmaceuticals, Sanofi, Akorn Inc, Merck Inc, VIVAN Life Sciences among others.

Why Purchase the Report?

• To visualize the global vernal keratoconjunctivitis market segmentation based on drug type, treatment type, dosage form, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of vernal keratoconjunctivitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global vernal keratoconjunctivitis market report would provide approximately 61 tables, 69 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies